Vigil Neuroscience to Present at 2022 Jefferies Global Healthcare Conference
June 01, 2022 07:00 ET
|
Vigil Neuroscience, Inc.
CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
Vigil Neuroscience Reports First Quarter 2022 Financial Results and Provides Business Highlights
May 12, 2022 07:00 ET
|
Vigil Neuroscience, Inc.
- Presented key findings enhancing clinical understanding of ALSP at the 2022 American Academy of Neurology Annual Meeting - - Expanded leadership team and board of directors with the appointments...
Vigil Neuroscience Expands Leadership Team and Board of Directors
April 20, 2022 07:00 ET
|
Vigil Neuroscience, Inc.
CAMBRIDGE, Mass., April 20, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
Vigil Neuroscience Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights
March 25, 2022 06:30 ET
|
Vigil Neuroscience, Inc.
- Completed successful initial public offering, raising $98 million in gross proceeds - - Initiated VGL101 Phase 1 trial; Phase 2 trial in ALSP patients expected to initiate in 2H 2022 - - Initiated...
Vigil Neuroscience to Present at Stifel 2022 CNS Days
March 21, 2022 07:00 ET
|
Vigil Neuroscience, Inc.
CAMBRIDGE, Mass., March 21, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
Vigil Neuroscience to Present Key Considerations for Lead Indication ALSP at the 2022 American Academy of Neurology Annual Meeting
March 03, 2022 16:05 ET
|
Vigil Neuroscience, Inc.
CAMBRIDGE, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
Vigil Neuroscience Announces Closing of Initial Public Offering
January 11, 2022 16:01 ET
|
Vigil Neuroscience, Inc.
CAMBRIDGE, Mass., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
Vigil Neuroscience Announces Pricing of Initial Public Offering
January 06, 2022 23:07 ET
|
Vigil Neuroscience, Inc.
CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...